You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 798 Real-world overall survival among patients receiving first-line (1L) pembrolizumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
798 Real-world overall survival among patients receiving first-line (1L) pembrolizumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to August 2024

AbstractFullPdf
Nov 2022188015
Dec 20224803
Jan 20235006
Feb 202368013
Mar 202370010
Apr 20233203
May 202394015
Jun 20235004
Jul 20233406
Aug 20235201
Sep 20235004
Oct 20237005
Nov 202310007
Dec 20238003
Jan 20243003
Feb 20244205
Mar 20245207
Apr 20243002
May 20246407
Jun 20244003
Jul 20243408
Aug 20243200
Total13100130